Compare Medtronic PLC (MDT) vs Rambus Inc. Common Stock (RMBS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Rambus Inc. Common Stock — how do they compare? Medtronic PLC trades at $95.5 (market cap $118.97B), while Rambus Inc. Common Stock trades at $89.17 (market cap $10.66B). The key difference: Medtronic PLC is far larger — about 11.2× Rambus Inc. Common Stock's market cap, and Medtronic PLC pays a 3.1% dividend while Rambus Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Rambus Inc. Common Stock for 0 Days on average.
| MDT | RMBS | |
|---|---|---|
Market Cap | $118.97B | $10.66B |
Volume | 24,932,018 | 2,136,075 |
Sector | Health | Technology |
52-Week High | $105.35 | $170.66 |
52-Week Low | $73.75 | $79.73 |
Typical Hold Time | 63 Days | 0 Days |
Enterprise Value | $138.31B | $9.85B |
Dividend Yield | 3.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $94.23, up 2.5% with strong technical momentum near resistance at $95. The stock shows solid fundamentals with consistent earnings beats, 13.93% net margins, and a 49-year dividend growth streak. Recent CPT code approvals for medical devices and raised 2026 guidance signal operational strength. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near-term.
MDT offers value with 3.2% dividend yield and 7%+ revenue growth, though debt levels have risen to 31.1% of assets. Analyst consensus remains strongly bullish (61% buy ratings) with $97.73 price target. Key risks include execution of the MiniMed separation and medical device competition. The stock presents a balanced opportunity for income and growth investors.
Rambus (RMBS) trades at $98.17, down 2.84% over 24 hours, with a neutral technical signal and key support at $96. The company reported strong profitability with a 31.69% net income margin and beat EPS estimates in two of the last three quarters. Recent news highlights its focus on AI infrastructure with new product launches, positioning it to benefit from growing demand for high-speed memory solutions.
The outlook is positive given analyst consensus of a $161.75 price target and 78.57% buy ratings, but risks include high valuation multiples and competitive pressures. Execution on AI-driven growth and maintaining earnings momentum are critical for stock appreciation, while any miss in upcoming results could pressure the premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Rambus Inc. Common Stock
Rambus Inc. is a semiconductor and silicon IP company that licenses chip interface and security technologies, including memory interface chipsets for DDR5 and DDR4 server and client DIMMs, interface IP for PCIe, CXL, and HBM, and security IP such as Root of Trust and memory encryption. It serves data center, AI, automotive, and IoT markets.
Read more on RMBS →
